Business
Avalo Reports 2024 Financial Results and Recent Business Updates
Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 Appointed Jennifer Riley as Chief Strategy Officer Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027 WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business up
About this update from Avalo Therapeutics, Inc.
[{"type":"image","alt":"Avalo Therapeutics","displaySize":"","headline":null,"caption":"Avalo Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":161,"url":"https://media.zenfs.com/en/globenewswire.com/64359ff9edc0e46c29be0915b2a0157e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ANi8XHp5jL2i.Q7JsBSgWw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/64359ff9edc0e46c29be0915b2a0157e","width":300,"height":161}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Topline data from Phase 2 LOTUS Trial of AVTX-009 for the treatment of hidradenitis suppurativa expected in 2026 ","length":112,"tagName":"p"}]},{"val":[{"type":"text","content":"Appointed Jennifer Riley as Chief Strategy Officer ","length":50,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash on hand of approximately $135 million as of December 31, 2024 expected to provide runway into at least 2027","length":112,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":274,"olType":false},{"type":"text","content":"WAYNE, Pa. and ROCKVILLE, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune dysregulation, today announced business updates and year-end financial results for 2024.","length":269,"tagName":"p"},{"type":"text","content":"“2024 was a transformational year for Avalo, and I am proud of the accomplishments the team has made in a short amount of time,” said Dr. Garry Neil, Chief Executive Officer and Chairman of the Board. “In March 2024, we acquired AVTX-009, a promising monoclonal antibody targeting interleukin-1β. We filed our IND application with the FDA, designed and launched the Phase 2 LOTUS trial in hidradenitis suppurativa (“HS”) and rapidly progressed its initiation, including IND activation in July and enrollment of the first patient in October. Our primary focus in 2025 is executing the LOTUS trial to release data in 2026, while exploring broader applications for AVTX-009 and announcing a second indication.”","length":707,"tagName":"p"},{"type":"text","content":"Recent Corporate Highlights and Upcoming Anticipated Milestones:","length":64,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Initiation of Phase 2 LOTUS trial: The gl...